SE8704097D0 - Oral formulation of buspirone and salts thereof - Google Patents

Oral formulation of buspirone and salts thereof

Info

Publication number
SE8704097D0
SE8704097D0 SE8704097A SE8704097A SE8704097D0 SE 8704097 D0 SE8704097 D0 SE 8704097D0 SE 8704097 A SE8704097 A SE 8704097A SE 8704097 A SE8704097 A SE 8704097A SE 8704097 D0 SE8704097 D0 SE 8704097D0
Authority
SE
Sweden
Prior art keywords
buspirone
salts
oral formulation
bioavailability
increase
Prior art date
Application number
SE8704097A
Other languages
English (en)
Inventor
A G M Nicklasson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE8704097A priority Critical patent/SE8704097D0/sv
Publication of SE8704097D0 publication Critical patent/SE8704097D0/sv
Priority to ZA887624A priority patent/ZA887624B/xx
Priority to IL88020A priority patent/IL88020A/xx
Priority to KR1019890701101A priority patent/KR970004906B1/ko
Priority to AT88850347T priority patent/ATE108997T1/de
Priority to PCT/SE1988/000543 priority patent/WO1989003676A1/en
Priority to DE3850844T priority patent/DE3850844T2/de
Priority to AU26236/88A priority patent/AU604585B2/en
Priority to JP63508883A priority patent/JP2674170B2/ja
Priority to HU886266A priority patent/HU204998B/hu
Priority to ES88850347T priority patent/ES2056955T3/es
Priority to EP88850347A priority patent/EP0313535B1/en
Priority to NZ238356A priority patent/NZ238356A/xx
Priority to NZ226604A priority patent/NZ226604A/en
Priority to YU196488A priority patent/YU47903B/sh
Priority to IE317788A priority patent/IE64705B1/en
Priority to PT88820A priority patent/PT88820B/pt
Priority to DK294489A priority patent/DK294489A/da
Priority to NO892512A priority patent/NO892512D0/no
Priority to FI893017A priority patent/FI100303B/sv
Priority to MX9203372A priority patent/MX9203372A/es
Priority to SG144094A priority patent/SG144094G/en
Priority to HK21295A priority patent/HK21295A/xx
Priority to CY181495A priority patent/CY1814A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
SE8704097A 1987-10-22 1987-10-22 Oral formulation of buspirone and salts thereof SE8704097D0 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE8704097A SE8704097D0 (sv) 1987-10-22 1987-10-22 Oral formulation of buspirone and salts thereof
ZA887624A ZA887624B (en) 1987-10-22 1988-10-12 Oral formulation of buspirone and salts thereof
IL88020A IL88020A (en) 1987-10-22 1988-10-12 Oral formulation of buspirone and salts thereof
EP88850347A EP0313535B1 (en) 1987-10-22 1988-10-17 Oral formulation of buspirone and salts thereof
ES88850347T ES2056955T3 (es) 1987-10-22 1988-10-17 Formulacion oral de buspirona y sales de la misma.
AT88850347T ATE108997T1 (de) 1987-10-22 1988-10-17 Orales präparat von buspiron und seinen salzen.
PCT/SE1988/000543 WO1989003676A1 (en) 1987-10-22 1988-10-17 Oral formulation of buspirone and salts thereof
DE3850844T DE3850844T2 (de) 1987-10-22 1988-10-17 Orales Präparat von Buspiron und seinen Salzen.
AU26236/88A AU604585B2 (en) 1987-10-22 1988-10-17 Oral formulation of buspirone and salts thereof
JP63508883A JP2674170B2 (ja) 1987-10-22 1988-10-17 ブスピロンおよびその塩の経口投与用組成物並びにその製造方法
HU886266A HU204998B (en) 1987-10-22 1988-10-17 Process for producing peroral pharmaceuticdal compositions comprising buspirone and its salts
KR1019890701101A KR970004906B1 (ko) 1987-10-22 1988-10-17 부스피론 및 그의 염의 경구 투여용 제제
NZ238356A NZ238356A (en) 1987-10-22 1988-10-18 Increasing the bioavailability of buspirone (an azaspirondecanedione) relative to its major metabolite by oral administration of a buspirone controlled/extended release formulation
NZ226604A NZ226604A (en) 1987-10-22 1988-10-18 Sustained release oral formulation containing buspirone as the active ingredient; process for preparation
IE317788A IE64705B1 (en) 1987-10-22 1988-10-20 Oral formulation of buspirone and salts thereof
YU196488A YU47903B (sh) 1987-10-22 1988-10-20 Postupak za pripremanje oralne formulacije za kontrolisano/produženo oslobadjanje buspirona i njegovih soli
PT88820A PT88820B (pt) 1987-10-22 1988-10-21 Processo para a preparacao de composicoes farmaceuticas de libertacao lenta e controlada contendo buspirona ou os seus sais para a administracao por via oral
DK294489A DK294489A (da) 1987-10-22 1989-06-15 Oralt indgiveligt laegemiddelpraeparat af buspiron og salte deraf
NO892512A NO892512D0 (no) 1987-10-22 1989-06-16 Oralt preparat av buspiron og salter derav.
FI893017A FI100303B (sv) 1987-10-22 1989-06-20 Förfarande för framställning av en oralt intagen buspiron och dess sal t
MX9203372A MX9203372A (es) 1987-10-22 1992-06-25 Composiciones farmaceuticas de buspirona y sales de la misma, de aplicacion oral.
SG144094A SG144094G (en) 1987-10-22 1994-10-05 Oral formulation of buspirone and salts thereof
HK21295A HK21295A (en) 1987-10-22 1995-02-16 Oral formulation of buspirone and salts thereof
CY181495A CY1814A (en) 1987-10-22 1995-10-20 Oral formulation of buspirone and salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8704097A SE8704097D0 (sv) 1987-10-22 1987-10-22 Oral formulation of buspirone and salts thereof

Publications (1)

Publication Number Publication Date
SE8704097D0 true SE8704097D0 (sv) 1987-10-22

Family

ID=20369959

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8704097A SE8704097D0 (sv) 1987-10-22 1987-10-22 Oral formulation of buspirone and salts thereof

Country Status (21)

Country Link
EP (1) EP0313535B1 (sv)
JP (1) JP2674170B2 (sv)
KR (1) KR970004906B1 (sv)
AT (1) ATE108997T1 (sv)
AU (1) AU604585B2 (sv)
CY (1) CY1814A (sv)
DE (1) DE3850844T2 (sv)
DK (1) DK294489A (sv)
ES (1) ES2056955T3 (sv)
FI (1) FI100303B (sv)
HK (1) HK21295A (sv)
HU (1) HU204998B (sv)
IE (1) IE64705B1 (sv)
IL (1) IL88020A (sv)
NO (1) NO892512D0 (sv)
NZ (1) NZ226604A (sv)
PT (1) PT88820B (sv)
SE (1) SE8704097D0 (sv)
WO (1) WO1989003676A1 (sv)
YU (1) YU47903B (sv)
ZA (1) ZA887624B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
JP2001517625A (ja) * 1997-09-25 2001-10-09 バイエル・アクチエンゲゼルシヤフト 活性成分放出制御薬物製剤
US6268368B1 (en) * 2000-03-01 2001-07-31 American Pharmaceuticals International Anionic exchange polymer complexes of buspirone
CN117257747B (zh) * 2023-11-21 2024-01-30 泊诺(天津)创新医药研究有限公司 一种盐酸丁螺环酮片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
SE353229B (sv) * 1970-06-04 1973-01-29 Haessle Ab
US4182703A (en) * 1978-01-09 1980-01-08 Eastman Kodak Company Biheterocyclic ultraviolet stabilizers and their use in organic compositions
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone

Also Published As

Publication number Publication date
NO892512L (no) 1989-06-16
HUT54495A (en) 1991-03-28
DK294489D0 (da) 1989-06-15
YU47903B (sh) 1996-05-20
ES2056955T3 (es) 1994-10-16
IL88020A0 (en) 1989-06-30
HU204998B (en) 1992-03-30
JP2674170B2 (ja) 1997-11-12
NO892512D0 (no) 1989-06-16
DE3850844D1 (de) 1994-09-01
PT88820B (pt) 1993-01-29
DK294489A (da) 1989-06-15
EP0313535B1 (en) 1994-07-27
WO1989003676A1 (en) 1989-05-05
IL88020A (en) 1993-08-18
AU604585B2 (en) 1990-12-20
EP0313535A1 (en) 1989-04-26
CY1814A (en) 1995-10-20
NZ226604A (en) 1991-07-26
IE64705B1 (en) 1995-08-23
ZA887624B (en) 1989-06-28
HK21295A (en) 1995-02-24
FI893017A (fi) 1989-06-20
HU886266D0 (en) 1991-01-28
YU196488A (en) 1990-04-30
DE3850844T2 (de) 1994-12-08
IE883177L (en) 1989-04-22
JPH02501744A (ja) 1990-06-14
ATE108997T1 (de) 1994-08-15
AU2623688A (en) 1989-05-23
KR970004906B1 (ko) 1997-04-08
KR890701087A (ko) 1989-12-19
FI893017A0 (fi) 1989-06-20
FI100303B (sv) 1997-11-14

Similar Documents

Publication Publication Date Title
DK367687A (da) Farmaceutisk praeparat til oral indgift med reguleret afgivelse og forlaenget virkning
IT1191674B (it) Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
DE69223914T2 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
FI872864A0 (sv) Förfarande för framställning av farmaceutiskt aktiva bensimidazolföreningar
DE69206495T2 (de) Matrixtablette zur verlängerten Indapamidfreisetzung nach oraler Gabe.
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
SE8704097D0 (sv) Oral formulation of buspirone and salts thereof
NO171412C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatiolan- eller 1,3-ditiolanderivater
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
NO169835C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive katecholkarboksylderivater
NO870950D0 (no) Fremgangsmaate for fremstilling av et stabilt injiserbart farmasoeytisk preparat.
NO172120C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoxazoler
BE880648A (fr) Nouvelles formes galeniques d'administration de medicaments par voie orale, aliberation programmee et leurs procedes de preparation
MX9203614A (es) Formulacion farmaceutica de liberacion controlada para administracion oral.
SE9002067D0 (sv) The pharmacological use of certain cystine derivatives
NO170541C (no) Analogiframgangsmaate for framstilling av terapeutisk aktive 1,5-benzotiazepinderivater
NO170017C (no) Analogiframgangsmaate for framstilling av terapeutisk aktive 1,5-benzotiazepinderivater
NO171210C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenofuran-derivater